Dose Conversion Ratio Between Roxadustat and Daprodustat in Patients With Non-dialysis Chronic Kidney Disease.

Authors

Keiji Hirai, Junki Morino, Katsunori Yanai, Yuko Mutsuyoshi, Taisuke Kitano, Haruhisa Miyazawa, Kiyonori Ito, Takahiro Masuda, Susumu Ookawara, Yoshiyuki Morishita

Published in

Cureus. Volume 18. Issue 8. Pages e114463. Epub Aug 13, 2026.

Abstract

This study aimed to determine the dose conversion ratio between roxadustat and daprodustat in non-dialysis chronic kidney disease (CKD) patients by switching from roxadustat to daprodustat.
Changes in hemoglobin, serum ferritin, transferrin saturation, and the doses of roxadustat and daprodustat were retrospectively analyzed in 15 patients (mean hemoglobin concentration: 11.2 ± 0.9 g/dL; mean estimated glomerular filtration rate: 14.3 ± 9.4 mL/min/1.73 m²; CKD stage G3b: 1, stage G4: 4, stage G5: 10) during the 12 months before and after switching from roxadustat to daprodustat.
Hemoglobin, serum ferritin concentrations, and transferrin saturation did not change after switching from roxadustat to daprodustat. The dose of roxadustat before switching was 51 ± 18 mg/administration, whereas the dose of daprodust at 12 months after switching was 5.2 ± 2.8 mg/administration. Accordingly, the dose conversion ratio between roxadustat and daprodustat was approximately 10:1 (51 ÷ 5.2 ≈ 10).
Our study results suggest that the dose conversion ratio between roxadustat and daprodustat is approximately 10:1 in non-dialysis CKD patients.

PMID:
42732353
Bibliographic data and abstract were imported from PubMed on 13 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.